OEM/ODM Solutions: Tailored Partnerships
Partner with us to unlock GLP-1 market opportunities through customized solutions and franchise support
Source Manufacturer
Custom Production
Bulk Supply
Trusted Partners
Leading global GLP-1 pharmaceutical R&D and manufacturing enterprise, serving over 500+ partners
International Standards
Complies with FDA, EMA, WHO pharmaceutical manufacturing standards ensuring product safety
Modern Facilities
100,000-class GMP clean workshops with annual production capacity exceeding 100 million units
Expert R&D Team
50+ pharmaceutical experts with multiple core technology patents for GLP-1 drugs
Cooperation Models
Flexible cooperation solutions to meet diverse client needs in the GLP-1 pharmaceutical market
OEM Branding Service
Complete OEM production service from product formulation to packaging design for your exclusive brand.
- Custom packaging design
- Flexible minimum order quantity
- Comprehensive production qualification
- International quality control standards
E-commerce Distribution
Comprehensive e-commerce support to help you quickly expand online sales channels.
- E-commerce platform entry support
- Professional product information package
- Marketing campaign planning
- Flexible pricing system
Offline Franchise
Comprehensive offline franchise support to help you establish stable regional sales networks.
- Exclusive regional distribution rights
- Professional market training
- Marketing materials support
- Comprehensive after-sales service
Our Advantages
Leveraging strong R&D capabilities and production capacity to provide comprehensive partner support
Production Advantages
Modern production facilities with advanced equipment, strictly adhering to international pharmaceutical manufacturing standards.
- 100,000-class GMP clean workshops meeting international standards
- Automated production lines with annual capacity exceeding 100 million units
- Strict quality control system with full traceability
- Responsive production scheduling to meet market demand
100,000-class GMP Clean Workshop
Professional R&D Team & Advanced Equipment
R&D Advantages
Professional R&D team with advanced equipment, continuously investing in new drug development.
- Professional R&D team of 50+ pharmaceutical experts
- Multiple core technology patents for GLP-1 drugs
- Continuous product innovation and optimization capabilities
- International standard R&D processes and specifications
Customization Advantages
Comprehensive customization services from product
formulation to packaging design.
- Flexible formula adjustment and specification customization
- Professional packaging design team for unique brand identity
- Small-batch trial production support to reduce market risk
- Responsive customization process for improved efficiency
Professional Custom Packaging Design
Professional After-sales Service Team
After-sales Advantages
Comprehensive after-sales support ensuring worry-free cooperation.
- 24/7 professional technical support hotline
- Regular product knowledge and market training
- Comprehensive return and exchange policy
- Timely notification of market trends and policy changes
Market Advantages
Strong market demand for GLP-1 drugs with significant efficacy, creating a blue ocean market
OEM Branding Service
Global obesity and diabetes rates continue to rise, creating strong demand for GLP-1 drugs with dual efficacy.
According to market research, the global GLP-1 drug market is expected to exceed $50 billion by 2025 with a CAGR exceeding 20%.
- 650 million obese and 463 million diabetic people worldwide
- GLP-1 drug market growing at over 20% annually
- Increasing consumer health awareness drives demand
Excellent Efficacy
GLP-1 drugs work through multiple mechanisms, effectively lowering blood sugar, promoting weight loss, and providing cardiovascular protection.
Clinical trials show GLP-1 drugs reduce HbA1c by 1-1.8%, weight by 5-15%, and significantly lower cardiovascular event risk.
- Dual efficacy: effective blood sugar control and significant weight loss
- Low risk of hypoglycemia and high safety profile
- Once-weekly administration for better patient compliance
- Cardiovascular protective effects with broad applicability
Global Market: Titans Clash as New Forces Emerge
The GLP-1 market is experiencing unprecedented growth driven by dual epidemics of diabetes and obesity worldwide
Market Surge: $51.8B in 2024 → $80B+ by 2030
The global GLP-1 drug market reached $51.8 billion in 2024, projected to grow to $60 billion in 2025, with expectations to surpass $80 billion by 2030. This explosive expansion is fueled by dual demands from over 1 billion obese individuals and 500+ million diabetic patients worldwide, compounded by accelerated policy endorsements and technological breakthroughs in dual-target therapies.
Therapeutic Validation: First-Line Status in 30+ Countries
GLP-1 drugs have been incorporated into diabetes first-line treatment guidelines across 30+ nations, establishing a robust foundation for widespread adoption. Policy-driven acceptance among physicians and patients continues to rise, further propelling market demand growth—evidenced by a 76% YoY increase in prescriptions for obesity indications.
Market Surge: $51.8B in 2024 → $80B+ by 2030
Global GLP-1 Market Growth Projection
Cooperation Process
Simple and efficient cooperation process to start your GLP-1 market journey
International Standards
Contact us to learn details and confirm cooperation intention
Solution Design
Customize cooperation plan based on your requirements
Sample Confirmation
Provide samples for testing and confirm quality
Contract Signing
Sign formal cooperation agreement
Production & Delivery
Arrange production, quality inspection and deliveryStart Cooperation Now
Success Stories
We've established long-term stable partnerships with numerous global partners
European Pharma Company
OEM Partnership
Provided semaglutide injection OEM services, helping enter GLP-1 market with annual sales exceeding €50 million.
Satisfaction 5.0
Asian E-commerce Platform
Distribution
Partnered with leading Asian pharmaceutical e-commerce platform, achieving ¥30 million sales within 6 months.
Satisfaction 4.8
